Sort by
Keyphrases
Warfarin
100%
Atrial Fibrillation
100%
Fracture Risk
100%
Anticoagulant Therapy
100%
Hazard Ratio
60%
Hip Fracture
40%
Apixaban
30%
Hospitalization
30%
Clinical Fractures
30%
Osteoporosis Diagnosis
30%
Low Risk
20%
Bone Health
20%
New User
20%
Non-valvular Atrial Fibrillation
20%
Comparative Safety
10%
Diabetes
10%
Hypertension
10%
High Risk
10%
Comparative Effectiveness
10%
Congestive Heart Failure
10%
Dabigatran Etexilate
10%
Oral Anticoagulants
10%
Real-world Population
10%
Vascular Disease
10%
Subgroup Analysis
10%
Rivaroxaban
10%
Multivariable
10%
Direct Oral Anticoagulants
10%
Propensity Score Matching
10%
International Classification of Diseases
10%
Total Fracture
10%
Confounding
10%
Disease Score
10%
Potential Adverse Effects
10%
Transient Ischemic Attack
10%
Administrative Claims Database
10%
Ninth Revision
10%
MarketScan
10%
Clinical Modification
10%
Previous Stroke
10%
High-dimensional Propensity Score
10%
Cardioembolic Complications
10%
Incident Fractures
10%
Cox Proportional Hazards Regression Model
10%
CHA2DS2-VASc
10%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
100%
Warfarin
100%
Atrial Fibrillation
100%
Hip Fracture
40%
Apixaban
30%
Cohort Study
10%
Direct Oral Anticoagulant
10%
Dabigatran Etexilate
10%
Cerebrovascular Accident
10%
Rivaroxaban
10%
Transient Ischemic Attack
10%
Congestive Heart Failure
10%
International Classification of Diseases
10%
Vascular Disease
10%